
Bryan A. Evans
Examiner (ID: 6981, Phone: (571)270-7022 , Office: P/3618 )
| Most Active Art Unit | 3618 |
| Art Unit(s) | 3613, 3618 |
| Total Applications | 1233 |
| Issued Applications | 977 |
| Pending Applications | 19 |
| Abandoned Applications | 254 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17554965
[patent_doc_number] => 11311622
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Development of masked therapeutic antibodies to limit off-target effects
[patent_app_type] => utility
[patent_app_number] => 16/460957
[patent_app_country] => US
[patent_app_date] => 2019-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 67
[patent_no_of_words] => 12852
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460957
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/460957 | Development of masked therapeutic antibodies to limit off-target effects | Jul 1, 2019 | Issued |
Array
(
[id] => 15800261
[patent_doc_number] => 20200123273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/451910
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451910
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/451910 | THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS | Jun 24, 2019 | Abandoned |
Array
(
[id] => 16949474
[patent_doc_number] => 20210208165
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/253821
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9169
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253821
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253821 | PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF | Jun 20, 2019 | Pending |
Array
(
[id] => 19779552
[patent_doc_number] => 12228582
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Method and apparatus for testing near infrared-photoimmunotherapy treatment
[patent_app_type] => utility
[patent_app_number] => 17/253671
[patent_app_country] => US
[patent_app_date] => 2019-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 3287
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253671
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253671 | Method and apparatus for testing near infrared-photoimmunotherapy treatment | Jun 19, 2019 | Issued |
Array
(
[id] => 16876875
[patent_doc_number] => 11026995
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-08
[patent_title] => Use of CD24 for lowering low-density lipoprotein cholesterol levels
[patent_app_type] => utility
[patent_app_number] => 16/443498
[patent_app_country] => US
[patent_app_date] => 2019-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 12
[patent_no_of_words] => 9195
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443498
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/443498 | Use of CD24 for lowering low-density lipoprotein cholesterol levels | Jun 16, 2019 | Issued |
Array
(
[id] => 15209891
[patent_doc_number] => 20190367632
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => THERAPEUTIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/427146
[patent_app_country] => US
[patent_app_date] => 2019-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37238
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16427146
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/427146 | Therapeutic antibodies | May 29, 2019 | Issued |
Array
(
[id] => 17975523
[patent_doc_number] => 11492371
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => Production of heterodimeric proteins
[patent_app_type] => utility
[patent_app_number] => 16/426647
[patent_app_country] => US
[patent_app_date] => 2019-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 115
[patent_figures_cnt] => 191
[patent_no_of_words] => 70663
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 206
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426647
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/426647 | Production of heterodimeric proteins | May 29, 2019 | Issued |
Array
(
[id] => 16948111
[patent_doc_number] => 20210206802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => MONOTHIOETHER CROSSLINKERS IN POLYMERS AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/250094
[patent_app_country] => US
[patent_app_date] => 2019-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6939
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250094
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/250094 | MONOTHIOETHER CROSSLINKERS IN POLYMERS AND APPLICATIONS THEREOF | May 29, 2019 | Abandoned |
Array
(
[id] => 17713513
[patent_doc_number] => 11377496
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-05
[patent_title] => Targeting agent antibody conjugates and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/420062
[patent_app_country] => US
[patent_app_date] => 2019-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 48
[patent_no_of_words] => 40190
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16420062
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/420062 | Targeting agent antibody conjugates and uses thereof | May 21, 2019 | Issued |
Array
(
[id] => 16861756
[patent_doc_number] => 11020478
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-01
[patent_title] => Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
[patent_app_type] => utility
[patent_app_number] => 16/416996
[patent_app_country] => US
[patent_app_date] => 2019-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 88
[patent_no_of_words] => 30852
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 199
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16416996
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/416996 | Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment | May 19, 2019 | Issued |
Array
(
[id] => 16221207
[patent_doc_number] => 20200246323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/412729
[patent_app_country] => US
[patent_app_date] => 2019-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -90
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16412729
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/412729 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | May 14, 2019 | Abandoned |
Array
(
[id] => 17482252
[patent_doc_number] => 20220089756
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS
[patent_app_type] => utility
[patent_app_number] => 17/053728
[patent_app_country] => US
[patent_app_date] => 2019-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053728
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/053728 | Bispecific antibodies with cleavable C-terminal charge-paired tags | May 7, 2019 | Issued |
Array
(
[id] => 15647219
[patent_doc_number] => 20200086139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
[patent_app_type] => utility
[patent_app_number] => 16/397104
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13831
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397104
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/397104 | COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA | Apr 28, 2019 | Abandoned |
Array
(
[id] => 15345347
[patent_doc_number] => 20200010565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-09
[patent_title] => TREATMENT OF OCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/395972
[patent_app_country] => US
[patent_app_date] => 2019-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16395972
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/395972 | TREATMENT OF OCULAR DISEASE | Apr 25, 2019 | Abandoned |
Array
(
[id] => 18340454
[patent_doc_number] => 20230132403
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-04-27
[patent_title] => FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/390912
[patent_app_country] => US
[patent_app_date] => 2019-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 234
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390912
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/390912 | FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF | Apr 21, 2019 | Abandoned |
Array
(
[id] => 18340454
[patent_doc_number] => 20230132403
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-04-27
[patent_title] => FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/390912
[patent_app_country] => US
[patent_app_date] => 2019-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 234
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390912
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/390912 | FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF | Apr 21, 2019 | Abandoned |
Array
(
[id] => 16198641
[patent_doc_number] => 10723791
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-28
[patent_title] => Compositions of isolated monoclonal antibodies and/or antigen-binding fragments thereof against indoxyl sulfate and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/388622
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 14
[patent_no_of_words] => 9825
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388622
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/388622 | Compositions of isolated monoclonal antibodies and/or antigen-binding fragments thereof against indoxyl sulfate and uses thereof | Apr 17, 2019 | Issued |
Array
(
[id] => 15649771
[patent_doc_number] => 20200087415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/383270
[patent_app_country] => US
[patent_app_date] => 2019-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16383270
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/383270 | HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS | Apr 11, 2019 | Abandoned |
Array
(
[id] => 16711960
[patent_doc_number] => 20210079107
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => ANTI-CD40 ANTIBODIES FOR USE IN PREVENTION OF GRAFT REJECTION
[patent_app_type] => utility
[patent_app_number] => 17/046684
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046684
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046684 | Anti-CD40 antibodies for use in prevention of graft rejection | Apr 10, 2019 | Issued |
Array
(
[id] => 16779381
[patent_doc_number] => 20210116459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => BIOMARKERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/046786
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5956
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046786
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046786 | BIOMARKERS AND USES THEREOF | Apr 10, 2019 | Abandoned |